2,4,6-trichloro-3-quinolinecarbonitrile | 876134-46-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,4,6-trichloro-3-quinolinecarbonitrile
• 英文别名: 2,4,6-trichloroquinoline-3-carbonitrile
• CAS: 876134-46-2
• 化学式: C₁₀H₃Cl₃N₂
• 分子量: 257.506
• InChiKey: GLTSYMLDDWUIJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4,6-trichloro-3-quinolinecarbonitrile 在 肼 作用下， 以 乙醇 为溶剂， 生成 4,8-dichloro-1H-pyrazolo[4,3-c]quinolin-3-amine
  参考文献：
  名称：

  Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity

  摘要：

  The direct inhibition of bacterial,beta-glucuronidase (beta G) activity is expected to reduce the reactivation of glucuronide-conjugated drugs in the intestine, thereby reducing drug toxicity. In this study, we report on the effects of pyrazolo [4,3-c] quinolines acting as a new class of bacterial beta G-specific inhibitors in a pH-dependent manner. Refinement of this chemotype for establishing structure-activity relationship resulted in the identification of potential leads. Notably, the oral administration of 3-amino-4-(4-fluorophenylamino)-1H-pyrazolo[4,3-c]quinoline (42) combined with chemotherapeutic CPT-11 treatment prevented CPT-11-induced serious diarrhea while maintaining the antitumor efficacy in tumor-bearing mice. Importantly, the inhibitory effects of 42 to E. coli beta G was reduced as the pH decreased due to the various surface charges of the active pocket of the enzyme, which may make their combination more favorable at neutral pH. These results demonstrate novel insights into the potent bacterial beta G-specific inhibitor that would allow this inhibitor to be used for the purpose of reducing drug toxicity.

  DOI：

  10.1021/acs.jmedchem.7b00963
• 作为产物：
  描述：

  2-氨基-5-氯苯甲酸甲酯 在 sodium methylate 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 19.0h， 生成 2,4,6-trichloro-3-quinolinecarbonitrile
  参考文献：
  名称：

  鉴定和表征氨基哌啶喹诺酮类和喹唑啉酮类作为MCHr1拮抗剂。

  摘要：

  已合成和评估了几种衍生自喹啉2（1H）-和喹唑啉-2（1H）-的功能强大的功能性MCHr1拮抗剂。喹诺酮1位上的吡啶基甲基取代导致衍生物具有较低的nM结合力和相对于hERG结合的良好选择性。

  DOI：

  10.1016/j.bmcl.2006.02.044

文献信息

• [EN] COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE<br/>[FR] COMPOSÉS UTILES POUR MODIFIER LES TAUX D'ACIDES BILIAIRES POUR LE TRAITEMENT DU DIABÈTE ET DE MALADIES CARDIOMÉTABOLIQUES.
  申请人：MERCK SHARP & DOHME

  公开号：WO2018034918A1

  公开（公告）日：2018-02-22

  Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

  本文描述了式（I）的化合物或其药用可接受的盐。式（I）的化合物作为Cyp8b1抑制剂，可用于预防、治疗或作为糖尿病和心血管疾病的治疗剂。
• Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10414775B2

  公开（公告）日：2019-09-17

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

  本文描述的是式 I 化合物或其药学上可接受的盐。式 I 的化合物作为 Cyp8b1 抑制剂，可用于预防、治疗或作为糖尿病和心血管疾病的补救药物。
• Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10414774B2

  公开（公告）日：2019-09-17

  Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as Cyp8b1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for diabetes and cardiovascular disease.

  本文描述的是式（I）化合物或其药学上可接受的盐。式 I 的化合物作为 Cyp8b1 抑制剂，可用于预防、治疗或作为糖尿病和心血管疾病的补救药物。
• Mekheimer, Ramadan Ahmed; Elgemeie, Galal Hamza; Kappe, Thomas, Journal of Chemical Research, 2005, # 2, p. 82 - 85
  作者：Mekheimer, Ramadan Ahmed、Elgemeie, Galal Hamza、Kappe, Thomas

  DOI：——

  日期：——
• COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLIC DISEASE
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3496715B1

  公开（公告）日：2021-11-03